S
Scott M. Lippman
Researcher at University of California, San Diego
Publications - 676
Citations - 66362
Scott M. Lippman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 109, co-authored 651 publications receiving 60987 citations. Previous affiliations of Scott M. Lippman include Cleveland Clinic & Columbia University.
Papers
More filters
Journal ArticleDOI
Corrigendum to “American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction” [Gynecol. Oncol. 115 (2009) 132–134]
TL;DR: Corrigendum to “American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction”.
Journal ArticleDOI
Three-Dimensional mRNA Measurements Reveal Minimal Regional Heterogeneity in Esophageal Squamous Cell Carcinoma
Wusheng Yan,Joanna Shih,Jaime Rodriguez-Canales,Michael A. Tangrea,Audrey Player,Lixia Diao,Nan Hu,Alisa M. Goldstein,Jing Wang,Philip R. Taylor,Scott M. Lippman,Ignacio I. Wistuba,Michael R. Emmert-Buck,Heidi S. Erickson +13 more
TL;DR: The present data indicate that, when analyzed using a standard array-based method at this level of histological resolution, ESCC contains little regional mRNA heterogeneity.
Book ChapterDOI
Biology and reversal of aerodigestive tract carcinogenesis.
TL;DR: Three principle modalities are currently used to control this disease: tobacco/alcohol cessation programs, surgery and radiotherapy for early and local-regional advanced disease, and chemotherapy in advanced, recurrent, and metastatic disease.
Journal ArticleDOI
Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus
Jens Luebeck,Alvin Wei Tian Ng,Patricia C. Galipeau,Xiaohong Li,Carissa A. Sanchez,Annalise Katz-Summercorn,Hoon Kim,Sriganesh Jammula,Yudou He,Scott M. Lippman,Roel G.W. Verhaak,Carlo C. Maley,Ludmil B. Alexandrov,Brian J. Reid,Rebecca C. Fitzgerald,Thomas G. Paulson,Howard Y. Chang,Sihan Wu,Vineet Bafna,Paul S. Mischel +19 more
TL;DR: In this article , the authors analyzed whole-genome sequencing (WGS) data from patients with oesophageal adenocarcinoma (EAC) or Barrett's o esophagus and found that the frequency of ecDNA increased between Barrett's-oesophagus-associated early-stage and late-stage (43%) EAC.
Proceedings ArticleDOI
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)
John V. Heymach,Pierre Saintigny,Edward S. Kim,Lauren Averett Byers,J. Jack Lee,Kevin R. Coombes,Lixia Diao,Jing Wang,Hai T. Tran,You H. Fan,Anne Tsao,George R. Blumenschein,Vassiliki A. Papadimitrakopoulou,Ximing Tang,Michael D. Story,Yang Xie,Luc Girard,John N. Weinstein,Li Mao,John D. Minna,Roy S. Herbst,Scott M. Lippman,Waun Ki Hong,Ignacio I. Wistuba +23 more
TL;DR: Gene expression profiling from CNBs is a feasible approach for predicting response and identifying activated oncogenic pathways and potential therapeutic targets in refractory NSCLC pts and merit further investigation as markers of benefit for EGFR inhibitors.